Abstract
High-dose chemotherapy (HDCT) followed by autologous blood stem cell transplantation is considered the treatment of choice for patients with relapsed or resistant aggressive non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD). However, several authors report failure of standard mobilization regimens in 29% to 56% of these patients making the completion of HDCT impossible and as a result, negatively influencing long-term outcome. Thus, effective new regimens for patients failing initial mobilization are needed. Here we report the results of using etoposide as a mobilizing agent in 16 patients with primary resistant or relapsed malignant lymphoma who had failed prior mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide (4 g/m2) followed by G-CSF. The use of etoposide 500 mg/m2 (days 1–4) + G-CSF resulted in the successful collection of adequate numbers of PBSC with a median harvest of 3.6 × 106/kg (range 2.2–12.6) CD34+ cells in all 16 patients. In 7/16 (44%) patients, the target yield of at least 2.0 × 106CD34+ cells was harvested by a single apheresis and the maximum number of separations for all patients was two. No excessive toxicities appeared, allowing all patients to proceed to myeloablative chemotherapy. In addition, median peak values of circulating CD34+cells were significantly higher after etoposide as compared to cyclophosphamide (49.2/μl vs4.7/μl; P = 0.0004). These results indicate that etoposide + G-CSF is a highly effective mobilization regimen in patients who have failed cyclophosphamide mobilization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reiser, M., Josting, A., Draube, A. et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 23, 1223–1228 (1999). https://doi.org/10.1038/sj.bmt.1701791
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701791
Keywords
This article is cited by
-
Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization
BMC Cancer (2020)
-
Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
BMC Cancer (2019)
-
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
Bone Marrow Transplantation (2016)
-
Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment
Annals of Hematology (2005)
-
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation
Bone Marrow Transplantation (2004)